Practical Considerations for Integrating Biosimilars Into Clinical Practice

The development of innovator biologics and now their biosimilars has created some unique challenges in oncology practice. The oncology advanced practitioner (OAP) must understand the key differences between the innovator biologic and biosimilars in regard to efficacy, safety, and immunogenicity. In...

Descripción completa

Detalles Bibliográficos
Autores principales: May, Megan B., TAUCHER, Kate Deen, Vogel, Wendy H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Practice Matters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163250/
https://www.ncbi.nlm.nih.gov/pubmed/34123479
http://dx.doi.org/10.6004/jadpro.2021.12.4.7
Descripción
Sumario:The development of innovator biologics and now their biosimilars has created some unique challenges in oncology practice. The oncology advanced practitioner (OAP) must understand the key differences between the innovator biologic and biosimilars in regard to efficacy, safety, and immunogenicity. In addition, the OAP must be able to evaluate and successfully navigate factors that may affect the adoption of biosimilars, such as the perceived cost-benefit and clinician and patient acceptance.

Ejemplares similares